ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Duchenne Muscular Dystrophy: Differentiating Advances in Treatment "
Episode Synopsis
CME credits: 0.25
Valid until: 29-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/duchenne-muscular-dystrophy-differentiating-advances-in-treatment/16654/
There are many unmet needs associated with the use of anti-inflammatory glucocorticoids when treating Duchenne muscular dystrophy, or DMD. These include multiple, often debilitating comorbidities that occur with long-term exposure. Join Drs. Hamid, Kuntz, and Monduy as they discuss key clinical trial data for a novel corticosteroid that may be a safer and possibly more effective option for patients with DMD than our current standard of care.=
Valid until: 29-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/duchenne-muscular-dystrophy-differentiating-advances-in-treatment/16654/
There are many unmet needs associated with the use of anti-inflammatory glucocorticoids when treating Duchenne muscular dystrophy, or DMD. These include multiple, often debilitating comorbidities that occur with long-term exposure. Join Drs. Hamid, Kuntz, and Monduy as they discuss key clinical trial data for a novel corticosteroid that may be a safer and possibly more effective option for patients with DMD than our current standard of care.=
In God we trust